Trial NRG-HN011


NRG-HN011: A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: Yes
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jacob Thomas, M.D.
Other Trial Staff:  Mary Ordaz, D.M., Kristy Sartor Massopust, Coordinator, Aida Lozada, Coordinator, Niranjan Bhatt, D.M., Sreebharathy Venkatesh, D.M., Sana Mutalib, Coordinator, Andrew Zeng, Coordinator, Thomas Won, Coordinator, Bomi Choi, Coordinator, Marie-Laure Gollier, D.M., Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.